Two Bespoke CAR-T Therapies Post Positive Data

Gilead and Bristol-Myers Squibb (BMS) are touting positive data from studies of their bespoke CAR-T cell treatments, each company hailing the results as a new treatment era for patients with relapsed or treatment-resistant large B-cell lymphoma.
Source: Drug Industry Daily